Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Dec 03, 2020 11:24am
93 Views
Post# 32026152

RE:RE:RE:RE:Piper Sandler Conf?

RE:RE:RE:RE:Piper Sandler Conf?I guess you had no reason to take a slot from someone else.  Hear any feedback, anything new?  Maybe the analyst will write up one of those Conf Notes kind of things in the next week.
I"m guessing it may have been Dubuc who did these since they just said "management" would present and not CEO specifically.  Maybe Marsolais. Hope they have refined the message and flow of their strategy to make it more convincing.  But as we've all said, for any new investor they will likely wait for confirmation of both Phase 3 commencing and oncology readouts.  They'll happily miss the first 100% to get a clearly picture for the next move.  Can't blame them. 


SPCEO1 wrote: The Piper conference turned out to be one on one meetings with portfolio managers on 12/1 and 12/2 and the Fireside Chat was the "presentation".  

Wino115 wrote:

I may be wrong but had thought that Fireside Chat with the analyst was a soft intro video and then there was an actual conference slot yesterday or today that was more detailed and maybe Q and A.     Not really sure though as I haven't seen any schedule for the conf.  





<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse